A low-anticoagulant heparin suppresses metastatic dissemination through the inhibition of tumor cell-platelets association

• Published in: Biomedicine & pharmacotherapy 2024-02, Vol.171, p.116108-116108, Article 116108
• Main Authors: Motta, Juliana M., Micheli, Kayene V.A., Roberto-Fernandes, Carlos, Hermsdorff-Brandt, Michelle, Guedes, Alessandra L., Frattani, Flávia S., Mourão, Paulo A.S., Pereira, Mariana S.
• Format: Article
• Language: English
• Subjects: Heparin; Metastasis; P-selectin; Platelets; Tumor cells
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.116108

Metastasis is the leading cause of cancer-related deaths. Despite this relevance, there is no specific therapy targeting metastasis. The interaction of the tumor cell with platelets, forming microemboli is crucial for successful hematogenous dissemination. Heparin disrupts it by a P-selectin-mediated event. However, its clinical use for this purpose is hindered by the requirement of high doses, leading to anticoagulant-related side effects. In this study, we obtained a low-anticoagulant heparin through the fractionation of a pharmaceutical bovine heparin. This derivative was referred to as LA-hep and we investigated its efficacy in inhibiting metastases and explored its capacity of suppressing the interaction between tumor cells and platelets. Our data revealed that LA-hep is as efficient as porcine unfractionated heparin in attenuating lung metastases from melanoma and colon adenocarcinoma cells in an assay with a single intravenous administration. It also prevents platelet arrest shortly after cell injection in wild-type mice and suppresses melanoma-platelets interaction in vitro. Moreover, LA-hep blocks P-selectin's direct binding to tumor cells and platelet aggregation, providing further evidence for the role of P-selectin as a molecular target. Even in P-selectin-depleted mice which developed a reduced number of metastatic foci, both porcine heparin and LA-hep further inhibited metastasis burden. This suggests evidence of an additional mechanism of antimetastatic action. Therefore, our results indicate a dissociation between the heparin anticoagulant and antimetastatic effects. Considering the simple and highly reproducible methodology used to purify LA-hep along with the data presented here, LA-hep emerges as a promising drug for future use in preventing metastasis in cancer patients. [Display omitted] ●Introduction of a low anticoagulant heparin (LA-hep) obtained from bovine heparin and devoid of bleeding effect.●A detailed characterization of LA-hep, including structure, average molecular weight, and its impact on in vivo hemostasis, is shown.●LA-hep demonstrated a remarkable capacity to inhibit metastatic dissemination in vivo.●LA-hep's antimetastatic activity is primarily based on the inhibition of tumor cell-platelet contact mediated by P-selectin.●LA-hep, safer than standard heparin, emerges as a promising candidate for the development of antitumoral therapies.